<DOC>
	<DOCNO>NCT01550471</DOCNO>
	<brief_summary>This study provide clinician guidance safe combination inhale nasal corticosteroid child mild asthma allergic rhinitis respectively ; however , one safety concern product independently know dose-related effect short term intermediate term growth . Knemometry non invasive technique measure short-term low leg growth child currently method choice growth study short duration . Subjects see weekly basis 18 week visit , low leg length measure use knemometry .</brief_summary>
	<brief_title>Sunovion Growth Study Pediatric Subjects With Mild Asthma &amp; Allergic Rhinitis</brief_title>
	<detailed_description>This single-center , cross-over study evaluate effect Omnaris Nasal Spray 200 mcg QD Alvesco Inhalation Aerosol 80 BID versus Beconase AQ Nasal Spray 168 mcg BID QVAR Inhalation Aerosol 40 mcg BID versus Placebo Nasal Spray QD Placebo Inhalation Aerosol BID short term growth pediatric subject mild asthma allergic rhinitis . During course study , subject see weekly basis lower leg length measure use knemometry . Knemometry non invasive technique measure short-term low leg growth child currently method choice growth study short duration . During run-in wash-out period , subject treat medication placebo . During active treatment period , subject treat Omnaris Nasal Spray 200 mcg QD Alvesco Inhalation Aerosol 80 BID Beconase AQ Nasal Spray 168 mcg BID QVAR Inhalation Aerosol 40 mcg BID , Placebo Nasal Spray QD Placebo Inhalation Aerosol BID . Eligible subject randomize study contain one run-in period ( Period 1 ) , 3 active treatment period ( Periods 2 , 4 6 ) 2 washout period ( Periods 3 5 ) . Each period 3 week duration entire study duration 18 week . Subjects see weekly basis 18 week visit , low leg length measure use knemometry .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>1 . Subjects include female male 12 15 year age . 2 . All subject must history physician diagnose mild asthma allergic rhinitis document PCP medical record detail history study investigator . 3 . All subject must height within normal limit ( 5th 95th percentile ) history abnormal growth assess medical history . 4 . Subjects may current treatment montelukast drug affect growth . If subject montelukast screening/baseline , remain stable dose throughout study . 5 . Subjects must willing comply study requirement . 1 . Subjects exclude asthma great mild persistent severity define NHLBI guideline . 2 Subjects exclude used systemic steroid within past 60 day . 3 . Subjects exclude one burst systemic steroid within past year . 4 . Subjects exclude baseline FEV1 &lt; 80 % predict . 5 . Subjects exclude serious systemic disease asthma . 6 . Subjects exclude take medication know affect growth i.e . ADHD medication within past 60 day 7 . Subjects exclude history allergy study medication . 8 . Subjects exclude active chickenpox measles recent exposure chickenpox measles . 9 . Subjects exclude history tuberculosis respiratory tract . 10 . Subjects exclude active fungal , bacterial , viral parasitic infection . 11 . Subjects exclude history herpes simplex infection eye . 12 . Subjects exclude take immunosuppressive drug within past 2 month . 13 . Subjects exclude history ChurgStrauss syndrome eosinophilic disorder . 14 . Subjects exclude investigator deems mental development health issue , autism , moderate severe mental retardation severe ADHD , interfere ability complete knemometry measurement . 15 . Subjects exclude investigator deems physical issue , inability sit independently amputation low leg , interfere ability complete knemometry measurement .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mild asthma allergic rhinitis</keyword>
</DOC>